Bortezomib activity and in vitro interactions with anthracyclines and cytarabine in acute myeloid leukemia cells are independent of multidrug resistance mechanisms and p53 status

@article{Minderman2006BortezomibAA,
  title={Bortezomib activity and in vitro interactions with anthracyclines and cytarabine in acute myeloid leukemia cells are independent of multidrug resistance mechanisms and p53 status},
  author={Hans Minderman and Yunfei Zhou and Kieran L. O’Loughlin and Maria R. Baer},
  journal={Cancer Chemotherapy and Pharmacology},
  year={2006},
  volume={60},
  pages={245-255}
}
The proteasome inhibitor bortezomib may be effective in combination with cytarabine and anthracyclines in the treatment of acute myeloid leukemia (AML) by virtue of targeting aberrantly activated NF-κB in AML stem cells. We tested whether bortezomib cytotoxicity is affected by multidrug resistance (MDR) proteins expressed in AML cells. We also tested whether bortezomib interactions with cytarabine and anthracyclines are affected by p53, because proteasome inhibition stabilizes p53 and may thus… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 41 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 39 references

Cyclosporine A is a broadspectrum multidrug resistance modulator

  • M Qadir, K O’Loughlin, NA Williamson, SM Fricke, H Minderman, MR Baer
  • Clin Cancer Res
  • 2005
Highly Influential
9 Excerpts

Similar Papers

Loading similar papers…